IRIS
GRAZIANI, GRAZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 82.291
EU - Europa 9.746
AS - Asia 9.624
SA - Sud America 1.138
AF - Africa 123
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 14
Totale 102.972
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 81.987
SG - Singapore 5.081
IT - Italia 2.686
CN - Cina 1.928
DE - Germania 1.225
UA - Ucraina 1.163
RU - Federazione Russa 1.008
BR - Brasile 945
FR - Francia 775
IE - Irlanda 748
HK - Hong Kong 688
VN - Vietnam 585
FI - Finlandia 453
SE - Svezia 439
GB - Regno Unito 434
PL - Polonia 362
KR - Corea 307
JP - Giappone 299
NL - Olanda 166
BD - Bangladesh 163
CA - Canada 157
IN - India 124
ID - Indonesia 82
MX - Messico 82
AR - Argentina 73
AT - Austria 50
TR - Turchia 47
ES - Italia 45
ZA - Sudafrica 44
IQ - Iraq 41
CZ - Repubblica Ceca 39
CO - Colombia 34
PH - Filippine 33
AU - Australia 30
IR - Iran 29
BE - Belgio 27
PK - Pakistan 27
AL - Albania 26
VE - Venezuela 24
EC - Ecuador 22
EG - Egitto 20
MA - Marocco 19
LT - Lituania 18
UZ - Uzbekistan 18
IL - Israele 17
MY - Malesia 17
KG - Kirghizistan 16
CL - Cile 15
JM - Giamaica 15
AE - Emirati Arabi Uniti 14
CH - Svizzera 14
SA - Arabia Saudita 13
EU - Europa 12
KE - Kenya 12
PE - Perù 12
BG - Bulgaria 11
JO - Giordania 10
KZ - Kazakistan 9
TW - Taiwan 9
NP - Nepal 8
TH - Thailandia 8
TN - Tunisia 8
BH - Bahrain 7
DK - Danimarca 7
DO - Repubblica Dominicana 7
PT - Portogallo 7
TT - Trinidad e Tobago 7
AZ - Azerbaigian 6
PS - Palestinian Territory 6
PY - Paraguay 6
RO - Romania 6
GE - Georgia 5
GT - Guatemala 5
LB - Libano 5
MK - Macedonia 5
NG - Nigeria 5
SY - Repubblica araba siriana 5
UY - Uruguay 5
BB - Barbados 4
BS - Bahamas 4
CR - Costa Rica 4
DZ - Algeria 4
HN - Honduras 4
HU - Ungheria 4
KH - Cambogia 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
OM - Oman 4
PA - Panama 4
SI - Slovenia 4
CY - Cipro 3
EE - Estonia 3
GR - Grecia 3
LU - Lussemburgo 3
RS - Serbia 3
BY - Bielorussia 2
ET - Etiopia 2
HR - Croazia 2
LK - Sri Lanka 2
LV - Lettonia 2
Totale 102.940
Salva come PNG Salva come JPEG
Città #
Woodbridge 24.331
Houston 19.901
Wilmington 19.896
Singapore 2.118
Ann Arbor 2.050
Fairfield 1.618
Ashburn 1.446
Chandler 1.044
Jacksonville 1.020
San Jose 916
Beijing 699
Dublin 691
Hong Kong 674
Seattle 654
Cambridge 549
New York 546
Medford 533
Rome 472
Dearborn 451
Santa Clara 332
Council Bluffs 316
The Dalles 314
Kraków 301
Dallas 264
Lawrence 255
Los Angeles 243
Tokyo 231
Helsinki 203
Milan 190
Ho Chi Minh City 179
Mülheim 176
Buffalo 149
Moscow 147
Hanoi 133
Menlo Park 127
Lauterbourg 112
Zhengzhou 97
San Diego 92
São Paulo 90
Boardman 86
Phoenix 66
Atlanta 63
Chicago 63
Nuremberg 61
Guangzhou 59
Mountain View 56
Redwood City 54
University Park 53
London 51
Jakarta 49
Falls Church 47
Frankfurt am Main 45
Munich 43
Nanjing 41
Naples 41
Shanghai 41
Hefei 40
Norwalk 40
Palo Alto 40
Toronto 39
Columbus 38
San Mateo 37
Orem 36
San Francisco 34
Warsaw 34
Brooklyn 33
Florence 33
Redondo Beach 33
Rio de Janeiro 31
Verona 31
Hangzhou 30
Denver 29
Xi'an 29
Johannesburg 27
Catania 26
Civitavecchia 26
Montreal 26
Brussels 25
Seoul 25
Belo Horizonte 24
Philadelphia 24
Stockholm 24
Ottawa 23
Prague 23
Kunming 22
North Bergen 22
Pisa 22
Mexico City 21
Boston 20
Campinas 20
Engelhard 20
Saint Petersburg 20
Salt Lake City 20
Baghdad 19
Bari 19
Turin 19
Kansas City 18
Pune 18
Amsterdam 17
Da Nang 17
Totale 85.653
Salva come PNG Salva come JPEG
Nome #
Gli inibitori della poli (ADP-ribosio) polimerasi (PARP) per superare la chemioresistenza a metilanti e inibitori di topoisomerasi I 1.568
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. 866
Parte V- Farmaci per il trattamento di infezioni, tumori e malattie immunologiche; Capitoli: 49, Principi di chemioterapia antimicrobica; 50, Farmaci antibatterici; 51, Farmaci antivirali; 52, Farmaci antifungini; 53, Farmaci antiprotozoari; 54, Farmaci anti-elmintici; 55, Farmaci antitumorali. Farmacologia, VII edizione Italiana di Rang and Dale's Pharmacology (VII ed. Inglese); p.616-680. 681
Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity 649
Influence of bacillus calmette-guerin (BCG) on induction of antigen-presenting cd1b molecule by granulocyte- macrophage colony stimulating factor (GM-CSF). 599
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? 593
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 553
Chimeric molecules between keratinocyte growth factor and basic fibroblast growth factor define domains that confer receptor binding specificities 550
Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells 538
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1 533
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report 531
Requirement of phospholipase C-catalyzed hydrolysis of phosphatidylcholine for maturation of Xenopus laevis oocytes in response to insulin and ras p21 529
Differential profile of NK target structures (NKTS) of mouse fibroblasts and lymphoma cells 524
Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of αvβ5 integrin. 521
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells 517
VIII edizione Rang & Dale's Pharmacology, edizione italiana Rang & Dale Farmacologia Edra LSWR Edizioni 9788821440397. 506
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells 505
BCG-infected adherent mononuclear cells release cytokines that regulate group 1 CD1 molecule expression 503
Bacillus Calmette-Guerin down-regulates CD1b induction by granulocyte-macrophage colony stimulating factor in human peripheral blood monocytes 500
Targeted therapy for brain tumours: role of PARP inhibitors 499
Adjuvant treatment of breast cancer: a pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha 495
Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells 492
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells 489
INVECCHIAMENTO, IMMUNITÀ E FARMACI 486
Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Associated Immunosenescence 484
5(2-bromovinyl)-2’-deoxyuridine (BVDU), increases the amount of chromatid breaks induced by bleomycin in mismatch repair deficient tumor cells by inhibiting homologous recombination 483
Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth 482
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide 481
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib 481
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity 480
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site 478
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome 477
I FARMACI E LA FRAGILITA’ 476
A novel water-soluble nitrobenzoxadiazole is highly effective against vemurafenib-resistant human melanoma cells 476
Traduzione e revisione capitoli di 38, 39, 40, 43, 48 e 56 della 10a edizione 2007 Inglese Basic and Clinical Pharmacology McGraw-Hill - Katzung corrispondente alla 7a edizione 2009 Italiana Piccin 472
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes 471
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds 471
Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro 471
Trattato di Medicina Interna Gasbarrini G. Volume 3 471
Challenging resistance mechanisms to therapies for metastatic melanoma 470
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. 469
Exogenous Control of the Expression of Group I CD1 Molecules Competent for Presentation of Microbial Nonpeptide Antigens to Human T Lymphocytes 469
Decline of natural cytotoxicity of human lymphocytes following infection with human T-cell leukemia/lymphoma virus (HTLV) 468
Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin 467
Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells 467
Immunopharmacology of antitumor agents. 463
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds 460
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies 460
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma 460
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 459
Emergence of double-positive CD4/CD8 cells from adult peripheral blood mononuclear cells infected with human T cell leukemia virus type I (HTLV-I) 459
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components 459
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells 459
Exploiting Microglial Functions for the Treatment of Glioblastoma 457
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes 455
Pharmacological strategies to increase the antitumor activity of methylating agents 454
Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. 454
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine 454
New aspects of immune responses against mycobacteria: immunopharmacology studies 454
Novel Glutathione S-Transferase Inhibitor Enhances Temozolomide Efficacy Against Malignant Melanoma 52nd Annual Meeting of the Italian Cancer Society. Lost in translation: bridging the gap between cancer research and effective therapies 453
Clinical perspectives of PARP inhibitors 451
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: Influence of 3'-azido-3'-deoxythymidine 451
In vitro infection of leukemic bone marrow with HTLV-I generates immortalized cell lines expressing T or myeloid cell phenotype 450
Role of GTPase activating protein in mitogenic signalling through phosphatidylcholine-hydrolysing phospholipase C 450
Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells 449
In vitro infection of CD4+ T lymphocytes with HTLV-I generates immortalized cell lines coexpressing lymphoid and myeloid cell markers 449
Capitoli 37, 38, 39, 55 di Farmacologia IX Ed. Italiana di Katzung B.G. Masters S.B. Trevor A.J. (XII Ed. Americana) 449
Modulation of GDF11 expression and synaptic plasticity by age and training 449
Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro 448
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma 447
Pharmacological modulation of carcinoembryonic antigen in human cancer cells: studies with staurosporine 446
Staurosporine increases carcinoembryonic antigen expression in a human colon cancer cell line 440
Role of PARP, NF-kB and telomerase in necrosis induced by selective methylation of N3-adenine. 439
Antigenic changes induced in tumor cells in vivo by dimethil-imidazole carboxamide (DTIC) 438
Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro 438
A region of proto-dbl essential for its transforming activity shows sequence similarity to a yeast cell cycle gene, CDC24, and the human breakpoint cluster gene, bcr 438
Monoclonal antibodies to CTLA-4 with focus on ipilimumab 437
Parte V- Farmaci per il trattamento di infezioni, tumori e malattie immunologiche (capitoli 49, 50, 51, 52, 53, 54, 55) Farmacologia VII edizione Italiana di Rang and Dale's Pharmacology (VII ed. Inglese). p. 616-680. 437
Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding 437
Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells 436
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines 436
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors 435
Apoptotic and clastogenic effects of methylating agents, alone or combined with poly(ADP-ribose) polymerase inhibitor, in peripheral blood lymphocytes 435
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy 434
Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. 434
NF-kB is activated in response to temozolomide and confers protection against drug-induced cell growth inhibition 433
5-Fluorouracil increases carcinoembryonic antigen expression and shedding in colon cancer cell clones with different basal levels of the molecule 433
Role of DNA repair pathways in the control of common fragile sites expression. 432
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. 432
DNA damaging agents can induce celll cycle arrest in different phases of mitosis 431
Neuropilin-1 as Therapeutic Target for Malignant Melanoma. 430
Activity against melanoma of an anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody that does not hamper ligand binding 430
Inhibition of O-6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic coils to apoptosis induced by temozolomide 429
Valproic acid inhibits proliferation and affects androgen sensitività in prostatic cancer cells 429
Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 429
Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen 428
Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells 428
Influence of Mycobacterium bovis bacillus Calmette Guérin on in vitro induction of CD1 molecules in human adherent mononuclear cells 428
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 428
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. 427
Totale 48.551
Salva come PNG Salva come JPEG
Categoria #
all - tutte 217.780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 217.780
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021185 0 0 0 0 0 0 0 0 0 0 0 185
2021/20222.502 97 322 177 131 67 201 143 135 204 174 120 731
2022/20233.220 331 188 77 401 262 759 271 206 296 48 270 111
2023/20241.826 168 41 94 90 146 590 146 77 61 55 104 254
2024/20257.332 235 1.362 659 357 244 495 289 394 711 379 1.190 1.017
2025/202611.133 768 465 1.317 707 939 385 1.193 1.516 1.354 983 909 597
Totale 103.558